|Day's Range||33.71 - 33.99|
|52 Week Range||25.55 - 35.60|
|PE Ratio (TTM)||25.42|
|Dividend & Yield||1.90 (5.62%)|
|1y Target Est||N/A|
LONDON (AP) — Anglo-Swedish drugmaker AstraZeneca says second-quarter revenue fell amid declining sales of blockbuster drugs Crestor and Seroquel XR, which lost patent protection in the United States last year.
AstraZeneca said a combination of two of its new oncology drugs failed to shrink lung cancer tumors in a closely watched clinical trial, casting doubt on a central part of the company’s ambitious growth ...
Shares lost more than 15% in the first minutes of trading.